Home » Investing in psychedelics: the decade’s most counterintuitive stock market bet

Investing in psychedelics: the decade’s most counterintuitive stock market bet

Golden tree with roots of stock charts and a colourful fractal crown symbolising investment in psychedelics

The psychedelic therapy market could grow from 3 billion to almost 13 billion dollars before 2035. These are the listed companies and the data you need before moving a single euro.

Some sectors grow quietly for years until a piece of data puts them on the map overnight. That is exactly what is happening with therapeutic psychedelics. On 17 February 2026, Compass Pathways published positive results in its two Phase 3 trials of synthetic psilocybin. Its shares rose more than 50% in a single day. The rest of the sector followed: GH Research and Helus Pharma rose about 12% the same day, and AtaiBeckley and Definium Therapeutics between 5% and 8%.

It was no accident. It was the confirmation of something the scientific community has been patiently building for years.

What exactly is being developed

When we talk about investing in psychedelics, we are not talking about buying mushrooms. We are talking about biotechnology companies developing synthetic, patentable formulations of compounds such as psilocybin, LSD, DMT or ketamine, putting them through rigorous clinical trials and seeking FDA and EMA regulatory approval for therapeutic use.

The model is identical to that of any pharmaceutical company: Phase 1 for safety, Phase 2 for efficacy, Phase 3 for large-scale confirmation, then an approval application. What changes is the compound and the clinical indication — resistant depression, PTSD, generalised anxiety, addictions.

Synthetic psilocybin accounts for 42% of all development deals in the sector. Ketamine, with its analogue already approved by the FDA under the name Spravato, comes second with 19%. They are the two most advanced horses in the race.

The listed companies and where they stand

Compass Pathways (NASDAQ: CMPS) is the most advanced name in the sector. Its drug COMP360, a synthetic, patented formulation of psilocybin, has completed two Phase 3 trials with positive results in resistant depression. It has received the FDA’s Breakthrough Therapy designation — a sign that regulators consider the compound promising — and the company expects to submit its approval application to the FDA between October and December 2026. It also received the green light in January 2026 to advance COMP360 in PTSD. It is the sector’s benchmark.

AtaiBeckley (NASDAQ: ATAI) was born from the merger of atai Life Sciences and Beckley Psytech. It has several candidates in Phase 2, including one based on nasal-spray mebufotenin for resistant depression, and a collaboration with Japanese pharmaceutical company Otsuka to develop R-ketamine — the first major alliance between a psychedelic biotech and a traditional pharmaceutical firm. Phase 2 results are expected in the second half of 2026.

Definium Therapeutics (NASDAQ: DFTX) is MindMed’s new name after its rebranding in January 2026. It has a synthetic LSD derivative called DT120 in three simultaneous Phase 3 trials — two for generalised anxiety disorder and one for major depression. First results are expected in the first half of 2026. Market capitalisation is around 700 million dollars.

GH Research (NASDAQ: GHRS) is betting on a different compound: mebufotenin, a very fast-acting psychedelic given by inhalation. The advantage is that the session lasts minutes instead of hours, which dramatically cuts the clinical cost per patient. It is in Phase 2b for resistant depression and Phase 2a for bipolar II disorder.

Helus Pharma (NYSE: CYBN) — formerly Cybin — develops its own molecules that act on the same receptors as psilocybin and DMT but with clearer patentability profiles. It has a catalogue of more than 50 candidates of its own, several in Phase 2, and has just closed a financing agreement of up to 500 million dollars with High Trail Special Situations to fund its trials.

The numbers behind the sector

The global psychedelic drugs market is estimated at 3.19 billion dollars in 2026 and projections point to 12.89 billion by 2035, with a compound annual growth rate of 15%. North America accounts for between 45% and 50% of the market. Since 2020, more than 275 million dollars in grants have gone to more than 500 research projects in the United States alone.

In 2025 Texas approved an allocation of up to 100 million dollars in state funds for ibogaine trials to treat opioid addiction. It is the first time a state government has directly funded psychedelic trials.

The risks you cannot ignore

None of these companies yet has an approved drug on the market. None is profitable. All depend on successive funding rounds that dilute shareholders. A failed trial can sink a share price by 60% in a day — as happened to Lykos Therapeutics when the FDA rejected its MDMA therapy for PTSD in August 2024. That company had to start again from scratch with a third Phase 3 trial.

The time horizon is also demanding. We are not talking about years but about lustrums. Investors who came in at the peak of euphoria in 2021 have been at a loss for years. Those who came in after the crash are better placed, but still need patience.

Where the real opportunity lies

The investment thesis is simple: if one or two of these compounds win FDA approval in the next 24 months — and Compass Pathways is on the shortest road to doing so — the sector will receive a regulatory validation that will unlock institutional capital that is still very cautious today. The effect will be similar to that of the first approval of a medical cannabis drug on the whole cannabis sector.

The difference is that here there is real science, real clinical trials and a mechanism of action that the world’s best research centres have been studying for a decade.

The risk is high. So is the asymmetry.

This article is for general information and is not financial advice. Before investing in biotechnology stocks, consult a qualified financial adviser.

Keep reading

Funded by the European Union - NextGenerationEURecovery, Transformation and Resilience Plan (Spain)

Funded by the European Union – NextGenerationEU